Mebendazole effectively overcomes imatinib resistance by dual-targeting BCR/ABL oncoprotein and β-tubulin in chronic myeloid leukemia cells. - Li Yang; Zhuanyun Du; Yuhang Peng; Wenyao Zhang; Wenli Feng; Ying Yuan (Korean Journal of Physiology & Pharmacology, 2025)